N/A N=197 Model 4396 Left Ventricular (LV) Lead Study
Heart Failure
Primary: Safety (Subjects Without a Model 4396 Lead Related Complication) — 155 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 Model 4296 Left Ventricular (LV) Lead Study
Heart Failure
Primary: Number of Participants With Left Ventricular (LV)Lead Related Complications — 1 participants
N/A N=190 Attain Model 4196 Left Ventricular (LV) Lead
Heart Failure
Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants
N/A N=22 InterventiOn of Biventricular Pacemaker Function on ventrIcular Function Among Patients With LVAD's
Heart Diseases · Left Ventricular Dysfunction
Primary: Peak Vo2 — 33; 12.5 ml/kg/min
N/A N=211 Identifying and Facilitating Ventricular Recovery on Mechanical Support
Heart Failure
Primary: Number of Subjects With Left Ventricular Recovery and LVAD Explant — 8 Participants
N/A N=15 Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices
Heart Failure
Primary: Peak Oxygen Uptake — 15 ml/kg/min
N/A N=20 Assessment of Left Ventricular Torsion by Echocardiography Study
Hypertrophic Cardiomyopathy
Primary: Accuracy of Doppler Tissue Imaging — 0.57 degrees
N/A N=60 Clinical Evaluation of LEft VEntricular Auto Threshold Algorithm (LEVEA)
Heart Failure
Primary: Percentage of Successful"In-Clinic LVAT" Test — 94.66 percentage of successful LVAT test
Phase 3 N=133 PUFAs and Left Ventricular Function in Heart Failure
Dilated Cardiomyopathy · Heart Failure
Primary: Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up — 36; 37; 39; 35…
N/A N=22 Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
Phase 2 N=25 Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement
Heart Failure
Primary: Safety of Cell Delivery — 1; 0 adverse events
Phase 2 N=16 Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
Left Ventricle Function
Primary: Left Ventricular Ejection Fraction (LVEF), Change From Baseline — 2.00; -3.25 Percent change
N/A N=101 Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™
Heart Failure
Primary: Six Minute Hall Walk (6MHW) Distance — -44.9; 69.7 meters — p=0.001
N/A N=120 Training-induced Increased Left Ventricular Trabeculation
Athletes Heart · Left Ventricular Hypertrabeculation
Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44
Phase 2 N=201 A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Hypertension, Pulmonary · Ventricular Dysfunction, Left
Primary: Pulmonary Artery Mean Pressure (PAPmean) at Rest - Change From Baseline to Week 16 — -6.1; -0.8; -4.5; -4.0 mmHg — p=0.1044
N/A N=200 Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy
Heart Failure, Congestive · Ventricular Dysfunction · Cardiomyopathies
Primary: Composite Endpoint — 46; 11 percentage of participants — p=0.00000025
N/A N=75 An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)
Ventricular Mural Thrombosis
Primary: Number of Participants With Left Ventricular Thrombus Resolution at 12 Weeks/Number of Participants at 12 Weeks — 50 Participants
Phase 4 N=76 Cardiovascular Function in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) in the 6th Week of Treatment — 2.855; 2.317 Millilitre/ meter^2 (mL/m^2) — p=0.6331
Phase 2 N=30 The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in Patients Undergoing LVAD Implantation
Heart Failure · Cardiomyopathy · Ventricular Dysfunction
Primary: Intervention Related Adverse Events — 0; 0 events
Phase 2 N=159 Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
Heart Failure · Cardiomyopathy · Ventricular Dysfunction
Primary: Number of Temporary Weans From LVAD Support Tolerated — 0.61; 0.58 number of weans
N/A N=121 Post-market Study of Multi-Vector Left Ventricular Lead Performance in Chinese Patients With Chronic Heart Failure
Chronic Heart Failure
Primary: The Number of Participants With LV Lead-related Serious Adverse Device Effects (SADEs) — 2 Participants
N/A N=165 Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy
Congenital Heart Disease
Primary: To Evaluate the Incidence of the Pre-proendothelin SNP at Nucleotide 5665 — 10 participants
N/A N=60 Hemodynamic Comparison of Tissue Aortic Valves
Aortic Valve Stenosis
Primary: Aortic Valve Mean Gradient (mm Hg) at Peak Exercise — 11; 14; 11 mm Hg
Phase 3 N=27 Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus
Left Ventricular Thrombosis
Primary: Percent Change in Left Ventricular Thrombus (LVT) Size — -61.45; -65.08 percentage of change
Phase 1 N=14 Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology
Hypoplastic Left Heart Syndrome · Single Ventricle · Heart Failure
Primary: Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells — 0; 0 participants
N/A N=111 Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation
Mitral Valve Insufficiency · Atrial Fibrillation · Heart Failure
Primary: Left Ventricular Filling Pressure More Than 15 mmHg Measured by Left Ventricular Catheterization — 25.5 mmHg
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Phase 2 N=58 Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction
Acute Myocardial Infarction
Primary: Change in Left Ventricular End-Systolic Volume Index — -2.1; -4.6 mL of blood/meter^2 body surface area — p=0.97
N/A N=27 Effects of Echo-optimization of Left Ventricular Assist Devices on Functional Capacity (VAFRACT)
Heart Failure
Primary: VO2 Peak — 13.2; 13.8; 14.2; 13.2 mL/Kg/min
N/A N=14 REmodeling the Left Ventricle With Atrial Modulated Pacing
Heart Failure
Primary: Number of Participants Who Remained on Study — 9; 4 participants